Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans

Deep brain stimulation of the subthalamic nucleus (STN‐DBS) has become an effective treatment option in advanced Parkinson's disease (PD). Recent animal studies showed an increase of neuronal firing in dopaminergic neurons under effective STN‐DBS. Increased striatal dopamine levels may also contribute to the stimulation's mechanism of action in humans. We investigated the striatal dopamine release in 6 patients with advanced PD under effective bilateral STN‐DBS with positron emission tomography (PET) of the reversible dopamine‐D2/3‐receptor ligand [11C]raclopride (RACLO). Although STN‐DBS proved to be a highly effective treatment in these subjects, we found no significant difference of the striatal RACLO binding between the STN‐DBS–on and –off condition. The changes of radioligand binding did not correlate with the patients' improvement in clinical rating scales or with the stimulation amplitudes. Therefore, our PET data in living parkinsonian humans do not provide evidence for an increased striatal dopamine concentration under effective STN‐DBS. We conclude that the modulation of dopaminergic activity does not seem to play a crucial role for the stimulation's mechanisms of action in parkinsonian humans. © 2002 Movement Disorder Society

[1]  Abdelhamid Benazzouz,et al.  High frequency stimulation of the STN influences the activity of dopamine neurons in the rat , 2000, Neuroreport.

[2]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[3]  M. Laruelle.  Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[5]  J R Moeller,et al.  Metabolic changes following subthalamotomy for advanced Parkinson's disease , 2001, Annals of neurology.

[6]  A. Lang,et al.  Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter‐ and intrarater reliability assessment , 1994, Movement disorders : official journal of the Movement Disorder Society.

[7]  Y. Michotte,et al.  Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists. , 1996, European journal of pharmacology.

[8]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  M. Hallett,et al.  Mechanism of action of deep brain stimulation. , 2000, Neurology.

[10]  A. Benabid,et al.  Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 1998, The New England journal of medicine.

[11]  Richard S. J. Frackowiak,et al.  Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease , 1997, Annals of neurology.

[12]  D. Brooks,et al.  Evidence for striatal dopamine release during a video game , 1998, Nature.

[13]  A L Benabid,et al.  From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. , 1999, Brain : a journal of neurology.

[14]  Marc Laruelle,et al.  Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates , 1992, Synapse.

[15]  D. Doudet.  Radionuclide Imaging in Parkinson’s Disease: Diagnosis, Treatment, and Disease Progression , 2001 .

[16]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[18]  H. Müller-Gärtner,et al.  Influence of Motor Activity on Striatal Dopamine Release: A Study Using Iodobenzamide and SPECT , 1999, NeuroImage.

[19]  Ornella Rimoldi,et al.  Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.

[20]  P. Krack,et al.  Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. , 2001, The New England journal of medicine.

[21]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[23]  A. Grace,et al.  The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. , 1995, Drug and alcohol dependence.

[24]  K Wienhard,et al.  The ECAT EXACT HR: Performance of a New High Resolution Positron Scanner , 1994, Journal of computer assisted tomography.

[25]  F. Windels,et al.  Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat , 2000, The European journal of neuroscience.

[26]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[27]  B Conrad,et al.  A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. , 1999, Archives of neurology.

[28]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[29]  U Pietrzyk,et al.  An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  A. Kupsch,et al.  Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats , 2001, Neuroscience Letters.

[31]  G. Di Chiara,et al.  Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  D. Bailey,et al.  3D acquisition and reconstruction in positron emission tomography , 1992, Annals of nuclear medicine.

[33]  Karl Herholz,et al.  A Method for Surface-Based Quantification of Functional Data from the Human Cortex , 1998 .

[34]  J S Fowler,et al.  Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.